• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602587)   Today's Articles (2345)   Subscriber (49368)
For: Rasaneh S, Rajabi H, Babaei MH, Daha FJ, Salouti M. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2009;36:363-9. [PMID: 19423003 DOI: 10.1016/j.nucmedbio.2009.01.015] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2008] [Revised: 01/18/2009] [Accepted: 01/31/2009] [Indexed: 11/20/2022]
Number Cited by Other Article(s)
1
Tunçel A, Maschauer S, Prante O, Yurt F. In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer. Pharmaceuticals (Basel) 2024;17:732. [PMID: 38931400 PMCID: PMC11206869 DOI: 10.3390/ph17060732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 05/27/2024] [Accepted: 06/01/2024] [Indexed: 06/28/2024]  Open
2
Amirdhanayagam J, Guleria M, Sharma R, Kumar N, Mukherjee A, Das T. Formulation of patient dose of [177Lu]Lu-Trastuzumab using in-house developed freeze-dried kit: A path forward for clinical translation. J Labelled Comp Radiopharm 2024;67:131-144. [PMID: 38342496 DOI: 10.1002/jlcr.4086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 02/13/2024]
3
Nakashima K, Watanabe H, Ono M. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates. J Med Chem 2023;66:12812-12827. [PMID: 37721492 DOI: 10.1021/acs.jmedchem.3c00472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/19/2023]
4
McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, Doshi P, Nakhla A, Bebawy M, Khalil D, Lotfalla A, Higgins H, Gulati A, Girard A, Bidard FC, Champion L, Duong P, Dercle L, Seban RD. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer. J Clin Med 2023;12:4882. [PMID: 37568284 PMCID: PMC10419459 DOI: 10.3390/jcm12154882] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 07/19/2023] [Accepted: 07/23/2023] [Indexed: 08/13/2023]  Open
5
Ebrahimi F, Noaparast Z, Abedi SM, Hosseinimehr SJ. Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging. Med Oncol 2022;39:204. [PMID: 36175805 DOI: 10.1007/s12032-022-01798-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 07/15/2022] [Indexed: 06/16/2023]
6
Postupalenko V, Marx L, Viertl D, Gsponer N, Gasilova N, Denoel T, Schaefer N, Prior JO, Hagens G, Lévy F, Garrouste P, Segura JM, Nyanguile O. Template directed synthesis of antibody Fc conjugates with concomitant ligand release. Chem Sci 2022;13:3965-3976. [PMID: 35440989 PMCID: PMC8985508 DOI: 10.1039/d1sc06182h] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Accepted: 02/16/2022] [Indexed: 11/29/2022]  Open
7
Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study. Nucl Med Commun 2021;42:1382-1395. [PMID: 34406146 DOI: 10.1097/mnm.0000000000001472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
8
Miranda ACC, dos Santos SN, Fuscaldi LL, Balieiro LM, Bellini MH, Guimarães MICC, de Araújo EB. Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties. Pharmaceutics 2021;13:971. [PMID: 34198999 PMCID: PMC8309196 DOI: 10.3390/pharmaceutics13070971] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 06/18/2021] [Accepted: 06/24/2021] [Indexed: 11/17/2022]  Open
9
Feng Y, Zhou Z, McDougald D, Meshaw RL, Vaidyanathan G, Zalutsky MR. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent. Nucl Med Biol 2020;92:171-183. [PMID: 32448731 DOI: 10.1016/j.nucmedbio.2020.05.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 05/06/2020] [Accepted: 05/07/2020] [Indexed: 11/28/2022]
10
Mortensen MR, Skovsgaard MB, Märcher A, Andersen VL, Palmfeldt J, Nielsen TB, Tørring T, Laursen NS, Andersen KR, Kjems J, Gothelf KV. Introduction of an Aldehyde Handle on Nanobodies by Affinity-Guided Labeling. Bioconjug Chem 2020;31:1295-1300. [PMID: 32320218 DOI: 10.1021/acs.bioconjchem.0c00151] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
11
Sharma R, Kameswaran M, Dash A. Comparative In Vitro Cytotoxicity Studies of 177Lu-CHX-A″-DTPA-Trastuzumab and 177Lu-CHX-A″-DTPA-F(ab')2-Trastuzumab in HER2-Positive Cancer Cell Lines. Cancer Biother Radiopharm 2020;35:177-189. [PMID: 32196365 DOI: 10.1089/cbr.2019.2882] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]  Open
12
Hermanto S, Haryuni RD, Ramli M, Mutalib A, Hudiyono S. Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F(ab′)2-trastuzumab for theranostic agent of HER2 positive breast cancer. JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES 2019. [DOI: 10.1016/j.jrras.2016.07.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
13
Preparation of 177Lu-Trastuzumab injection for treatment of breast cancer. Appl Radiat Isot 2019;148:184-190. [PMID: 30974402 DOI: 10.1016/j.apradiso.2019.04.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 03/28/2019] [Accepted: 04/02/2019] [Indexed: 11/21/2022]
14
Mishiro K, Hanaoka H, Yamaguchi A, Ogawa K. Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications. Coord Chem Rev 2019. [DOI: 10.1016/j.ccr.2018.12.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
15
Mortensen MR, Nielsen NL, Palmfeldt J, Gothelf KV. Imidazole carbamate probes for affinity guided azide-transfer to metal-binding proteins. Org Biomol Chem 2019;17:1379-1383. [DOI: 10.1039/c8ob03017k] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
16
Massicano AVF, Marquez-Nostra BV, Lapi SE. Targeting HER2 in Nuclear Medicine for Imaging and Therapy. Mol Imaging 2018;17:1536012117745386. [PMID: 29357745 PMCID: PMC5784567 DOI: 10.1177/1536012117745386] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 09/17/2017] [Accepted: 09/22/2017] [Indexed: 12/21/2022]  Open
17
Moreau M, Poty S, Vrigneaud JM, Walker P, Guillemin M, Raguin O, Oudot A, Bernhard C, Goze C, Boschetti F, Collin B, Brunotte F, Denat F. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. Dalton Trans 2017;46:14659-14668. [DOI: 10.1039/c7dt01772c] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
18
Kameswaran M, Gota V, Ambade R, Gupta S, Dash A. Preparation and preclinical evaluation of 131 I-trastuzumab for breast cancer. J Labelled Comp Radiopharm 2016;60:12-19. [PMID: 27813128 DOI: 10.1002/jlcr.3465] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2016] [Revised: 08/30/2016] [Accepted: 09/08/2016] [Indexed: 11/10/2022]
19
Gebhart G, Flamen P, De Vries EGE, Jhaveri K, Wimana Z. Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. J Nucl Med 2016;57 Suppl 1:81S-8S. [PMID: 26834107 DOI: 10.2967/jnumed.115.157941] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
20
Adeowo FY, Honarparvar B, Skelton AA. The interaction of NOTA as a bifunctional chelator with competitive alkali metal ions: a DFT study. RSC Adv 2016. [DOI: 10.1039/c6ra20203a] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]  Open
21
Synthesis of a stabilized 177Lu–siRNA complex and evaluation of its stability and RNAi activity. Nucl Med Commun 2015;36:636-45. [DOI: 10.1097/mnm.0000000000000292] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
22
Rasaneh S, Rajabi H, Johari Daha F. Activity estimation in radioimmunotherapy using magnetic nanoparticles. Chin J Cancer Res 2015;27:203-8. [PMID: 25937783 DOI: 10.3978/j.issn.1000-9604.2015.03.06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 12/11/2014] [Indexed: 11/14/2022]  Open
23
Schjoeth-Eskesen C, Nielsen CH, Heissel S, Højrup P, Hansen PR, Gillings N, Kjaer A. [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. J Labelled Comp Radiopharm 2015;58:227-33. [PMID: 25906708 PMCID: PMC5029596 DOI: 10.1002/jlcr.3287] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 03/10/2015] [Accepted: 03/11/2015] [Indexed: 12/28/2022]
24
Banerjee S, Pillai MRA, Knapp FFR. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 2015;115:2934-74. [PMID: 25865818 DOI: 10.1021/cr500171e] [Citation(s) in RCA: 157] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
25
Dash A, Pillai MRA, Knapp FF. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging 2015;49:85-107. [PMID: 26085854 DOI: 10.1007/s13139-014-0315-z] [Citation(s) in RCA: 141] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 12/20/2014] [Accepted: 12/23/2014] [Indexed: 10/24/2022]  Open
26
Aspects of yield and specific activity of (n,γ) produced 177Lu used in targeted radionuclide therapy. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3240-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
27
Novy Z, Laznickova A, Mandikova J, Barta P, Laznicek M, Trejtnar F. The effect of chelator type onin vitroreceptor binding and stability in177Lu-labeled cetuximab and panitumumab. J Labelled Comp Radiopharm 2014;57:448-52. [DOI: 10.1002/jlcr.3204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 02/01/2014] [Accepted: 04/11/2014] [Indexed: 11/06/2022]
28
Physical optimization of production by deuteron irradiation of high specific activity 177gLu suitable for radioimmunotherapy. Nucl Med Biol 2014;41:407-9. [DOI: 10.1016/j.nucmedbio.2014.02.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2013] [Revised: 02/20/2014] [Accepted: 02/21/2014] [Indexed: 11/18/2022]
29
On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3169-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
30
Demonstration of dose dependent cytotoxic activity in SW480 colon cancer cells by ¹⁷⁷Lu-labeled siRNA targeting IGF-1R. Nucl Med Biol 2013;40:529-36. [PMID: 23618769 DOI: 10.1016/j.nucmedbio.2012.05.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Revised: 04/28/2012] [Accepted: 05/03/2012] [Indexed: 11/24/2022]
31
Das T, Pillai M. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 2013;40:23-32. [DOI: 10.1016/j.nucmedbio.2012.09.007] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 09/05/2012] [Accepted: 09/10/2012] [Indexed: 01/09/2023]
32
Kumrić KR, Vladisavljević GT, Trtić-Petrović TM. Membrane-Assisted Liquid-Phase Extraction of Lu(III) in a U-Shaped Contactor with a Single Hollow Fiber Membrane. Ind Eng Chem Res 2012. [DOI: 10.1021/ie301887h] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
33
Bejot R, Goggi J, Moonshi SS, Padmanabhan P, Bhakoo KK. Aminooxy-functionalized DOTA for radiolabeling of oxidized antibodies: evaluation of site-specific 111In-labeled trastuzumab. J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.2950] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
34
Ashrafi SA, Hosseinimehr SJ, Varmira K, Abedi SM. Radioimmunotherapy with ¹³¹I-bevacizumab as a specific molecule for cells with overexpression of the vascular endothelial growth factor. Cancer Biother Radiopharm 2012;27:420-5. [PMID: 22690909 DOI: 10.1089/cbr.2012.1224] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
35
Moreau M, Raguin O, Vrigneaud JM, Collin B, Bernhard C, Tizon X, Boschetti F, Duchamp O, Brunotte F, Denat F. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes. Bioconjug Chem 2012;23:1181-8. [PMID: 22519915 DOI: 10.1021/bc200680x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
36
Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals (Basel) 2011;5:1-15. [PMID: 22229017 PMCID: PMC3250925 DOI: 10.3390/ph5010001] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
37
Salouti M, Babaei MH, Rajabi H, Rasaee MJ. Preparation and biological evaluation of 177Lu conjugated PR81 for radioimmunotherapy of breast cancer. Nucl Med Biol 2011;38:849-55. [DOI: 10.1016/j.nucmedbio.2011.02.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Revised: 02/16/2011] [Accepted: 02/16/2011] [Indexed: 10/18/2022]
38
Vera DRB, Eigner S, Beran M, Henke KE, Laznickova A, Laznicek M, Melichar F, Chinol M. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm 2011;26:287-97. [PMID: 21711096 DOI: 10.1089/cbr.2010.0916] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
39
Wong JYC, Raubitschek A, Yamauchi D, Williams LE, Wu AM, Yazaki P, Shively JE, Colcher D, Somlo G. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm 2011;25:387-94. [PMID: 20707718 DOI: 10.1089/cbr.2010.0783] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
40
Manenti S, Groppi F, Gandini A, Gini L, Abbas K, Holzwarth U, Simonelli F, Bonardi M. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177gLu in no-carrier-added form for metabolic radiotherapy. Appl Radiat Isot 2011;69:37-45. [DOI: 10.1016/j.apradiso.2010.08.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2010] [Revised: 07/23/2010] [Accepted: 08/10/2010] [Indexed: 11/17/2022]
41
Rasaneh S, Rajabi H, Babaei MH, Daha FJ. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2010;37:949-55. [PMID: 21055626 DOI: 10.1016/j.nucmedbio.2010.07.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2010] [Revised: 05/30/2010] [Accepted: 07/01/2010] [Indexed: 11/27/2022]
42
Rasaneh S, Rajabi H, Babaei MH, Johari Daha F. Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model. J Labelled Comp Radiopharm 2010. [DOI: 10.1002/jlcr.1780] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
43
Rasaneh S, Rajabi H, Hossein Babaei M, Johari Daha F. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines. Appl Radiat Isot 2010;68:1964-6. [PMID: 20537546 DOI: 10.1016/j.apradiso.2010.05.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2009] [Revised: 04/11/2010] [Accepted: 05/06/2010] [Indexed: 11/16/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA